1. [P4–567]: A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812. (1st July 2017) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Guttendorf, Robert; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 32 Page Start: P1570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Issue 1 (18th December 2018) Authors: Grundman, Michael; Morgan, Roger; Lickliter, Jason D.; Schneider, Lon S.; DeKosky, Steven; Izzo, Nicholas J.; Guttendorf, Robert; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Safferstein, Hank; Catalano, Susan M. Journal: Alzheimer's & dementia Issue: Volume 5:Issue 1(2019) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity. Issue 4 (25th October 2020) Authors: Limegrover, Colleen S.; LeVine, Harry; Izzo, Nicholas J.; Yurko, Raymond; Mozzoni, Kelsie; Rehak, Courtney; Sadlek, Kelsey; Safferstein, Hank; Catalano, Susan M. Journal: Journal of neurochemistry Issue: Volume 157:Issue 4(2021) Page Start: 1316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P4‐381: A Two‐Part, Double‐Blind, Placebo‐Controlled, Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers. (1st July 2016) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank; Lickliter, Jason Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2014)Part 24 Page Start: P1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812. (1st July 2019) Authors: Schneider, Lon S.; Caggiano, Anthony O.; Grundman, Michael; DeKosky, Steve; Morgan, Roger; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank; Catalano, Susan Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 31 Page Start: P1603 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Issue 8 (8th February 2021) Authors: Izzo, Nicholas J.; Yuede, Carla M.; LaBarbera, Kelsie M.; Limegrover, Colleen S.; Rehak, Courtney; Yurko, Raymond; Waybright, Lora; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Hamby, Mary E.; Williams, Claire; Sadlek, Kelsey; Edwards, Hannah M.; Davis, Charles S.; Grundman, Michael; Schneide... Journal: Alzheimer's & dementia Issue: Volume 17:Issue 8(2021) Page Start: 1365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain‐derived α‐synuclein. Issue 4 (22nd January 2021) Authors: Limegrover, Colleen S.; Yurko, Raymond; Izzo, Nicholas J.; LaBarbera, Kelsie M.; Rehak, Courtney; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Catalano, Susan M. Journal: Journal of neuroscience research Issue: Volume 99:Issue 4(2021) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗